- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04830969
Impact of Periodontal Therapy on Patients With Diabetes (DMRCT)
Impact of Periodontal Therapy on Patients With Diabetes: A Pilot Study
With poorly controlled diabetes, periodontal status often worsens, and with severe periodontal conditions there is often poorer glycemic control. There are few published reports investigating the efficacy of periodontal therapy in diabetics and fewer that include evaluation of the oral microbial profiles (the microbiome). The investigators will examine systemic changes in diabetes status and microbiome influences on clinical response to periodontal therapy in a randomized clinical trial of participants with and without diabetes and with periodontal disease. Two different treatments will be used:
- Scaling and root planning (SRP) alone, or
- SRP and supportive periodontal therapy (SPT), the use of chlorhexidine gluconate rinse (Paroex®) and a rubber interdental bristle cleaner (Soft-Picks) The main goal of this clinical trial is to evaluate the effects of SRP alone versus SRP+SPT on clinical, microbiological and immunological status in participants. A clearer understanding of how periodontal therapy affects diabetes status could lead to the development of new therapies for periodontal disease and diabetes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
With poorly controlled diabetes, periodontal disease worsens, and with severe periodontal conditions, there is often poorer glycemic control. Published papers conclude that periodontal treatment leads to a reduction in hemoglobin A1c; however, other studies show limited or no improvement. Some patients do not respond well to professional periodontal therapy, even without diabetes, which could be related to poor oral hygiene and/or host factors including microbial profiles. There are few published papers investigating the efficacy of periodontal therapy in diabetics and fewer that include assessment of the oral microbiome. The investigators will examine systemic changes in diabetes status and microbiome influences on clinical response to periodontal therapy in a randomized clinical trial. It has been shown that chlorhexidine gluconate rinse leads to significant clinical improvement over standard periodontal therapy alone, and interdental tooth cleaners remove more dental plaque (leading to reduced gingival inflammation) effectively than brushing alone. Therefore, in this study, standard periodontal therapy, scaling and root planning (SRP) will be provided alone, or SRP plus supportive periodontal therapy (SPT), the use of chlorhexidine gluconate rinse (Paroex®) and a rubber interdental bristle cleaner (Soft-Picks), to diabetics and non-diabetics with periodontal disease to determine the differences in response between the groups.
The main aim of this study is to evaluate the effects of SRP alone versus SRP+SPT on clinical, microbiological and immunological status of subjects with and without type 2 diabetes and with periodontal disease. A clearer understanding of how periodontal therapy affects diabetes status could lead to the development of novel new targeted therapies of both periodontal disease and diabetes.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14214
- University at Buffalo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be able to understand the informed consent form and be willing and able to read and sign it.
- At least 25 years of age.
- Be able to understand and follow directions for study procedures.
- At least 14 natural teeth, not counting third molars ("wisdom teeth").
- At least 2 interproximal sites with CAL >= 4 mm or at least 2 interproximal sites with PD >= 5 mm.
Exclusion Criteria:
- Presence of orthodontic appliances ("braces").
- An abnormal condition of lips, lining of the mouth, tongue, or gums (except for periodontal disease). If subject has a cold sore, canker sore, or injury in their mouth, they may return after the sore or injury heals.
- Abscess of the gingiva caused by periodontal disease, or visible gross tooth decay
- A broken tooth root or an abscessed tooth. Subject may be allowed to participate in the study after the condition is successfully treated.
- Periodontal treatment or antibiotic therapy in the past 6 months.
- Have used cigarettes or other tobacco products in the past year.
- Body mass index (BMI) is > 40.
- Have regularly used non-steroidal anti-inflammatory drugs (such as >= 325 mg aspirin or ibuprofen) over the past 3 weeks.
- Regularly using drugs that weaken the immune system (such as corticosteroids taken by mouth or injection, and cyclosporine).
- Have participated in another clinical research study in the past 30 days.
- Pregnant or breastfeeding.
- Have a condition that we feel will make study participation unsafe or difficult for the patient.
- Require premedication for dental exams.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A: Diabetic + SRP + SPT
The first group, A, includes diabetics with periodontal disease; they will receive standard therapy, scaling & root planing plus supportive periodontal therapy (SPT) chlorhexidine gluconate (Paroex®) mouthrinse + Soft-Picks.
|
Paroex® is a non-alcohol chlorhexidine preparation.
Participants are to use 15 mL morning and evening for 3 months.
With use of chlorhexidine, there is risk of reversible staining of teeth and the possibility of some alteration in taste.
There is increased likeliness of staining in smokers, coffee drinkers and those who are susceptible to teeth staining in general.
The cleaning of the front teeth is provided at the 3-month visit and helps to reduce any staining that may occur.
If there is any alteration in taste, it should go away when use of chlorhexidine stops.
Other Names:
SRP is standard treatment of periodontitis.
It involves using a scaler to remover subgingival plaque and other debris in the space between teeth and gums.
Other Names:
Soft Picks are a rubber interdental bristle cleaner.
Participants are to use Soft Picks morning and evening for all 12 months of the study.
They may cause some bleeding of the gums at first usage, but the bleeding should lessen and stop as use is continued (as gums heal).
Soft-Picks are a readily available consumer product sold in supermarkets and drug stores.
|
Experimental: B: Non-Diabetic + SRP + SPT
The second group, B, includes non-diabetics with periodontal disease; they will receive standard therapy, scaling & root planing plus supportive periodontal therapy (SPT) chlorhexidine gluconate (Paroex®) mouthrinse + Soft-Picks.
|
Paroex® is a non-alcohol chlorhexidine preparation.
Participants are to use 15 mL morning and evening for 3 months.
With use of chlorhexidine, there is risk of reversible staining of teeth and the possibility of some alteration in taste.
There is increased likeliness of staining in smokers, coffee drinkers and those who are susceptible to teeth staining in general.
The cleaning of the front teeth is provided at the 3-month visit and helps to reduce any staining that may occur.
If there is any alteration in taste, it should go away when use of chlorhexidine stops.
Other Names:
SRP is standard treatment of periodontitis.
It involves using a scaler to remover subgingival plaque and other debris in the space between teeth and gums.
Other Names:
Soft Picks are a rubber interdental bristle cleaner.
Participants are to use Soft Picks morning and evening for all 12 months of the study.
They may cause some bleeding of the gums at first usage, but the bleeding should lessen and stop as use is continued (as gums heal).
Soft-Picks are a readily available consumer product sold in supermarkets and drug stores.
|
Active Comparator: C: Diabetic + SRP
The third group, C, includes diabetics with periodontal disease; they will receive standard therapy, scaling and root planing (SRP).
|
SRP is standard treatment of periodontitis.
It involves using a scaler to remover subgingival plaque and other debris in the space between teeth and gums.
Other Names:
|
Active Comparator: D: Non-Diabetic + SRP
The second group, D, includes non-diabetics with periodontal disease; they will receive standard therapy, scaling and root planing (SRP).
|
SRP is standard treatment of periodontitis.
It involves using a scaler to remover subgingival plaque and other debris in the space between teeth and gums.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Probing Pocket Depth at the 6-month Post-SRP Completed at Baseline
Time Frame: Baseline to 6 months
|
Periodontal PD in millimeters is measured with a UNC-15 periodontal probe on 6 sites per tooth; site status is compared between timepoints measured
|
Baseline to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Probing Pocket Depth at the 3-month Post-SRP Completed at Baseline
Time Frame: Baseline to 3 months
|
Periodontal PD in millimeters is measured with a UNC-15 periodontal probe on 6 sites per tooth; site status is compared between timepoints measured
|
Baseline to 3 months
|
Changes in Clinical Attachment Level at 3, 6 Months After Treatment at Baseline
Time Frame: Baseline to 3 months;Baseline to 6 months
|
The distance from the Cemento-enamel Junction (CEJ) to the free gingival margin is measured with a periodontal probe.
Millimeters of recession (loss of attachment) is recorded as a negative number; when the gingival margin is above the CEJ, the measurement (in millimeters) is recorded as positive.
|
Baseline to 3 months;Baseline to 6 months
|
Change in % Sites With Probing Pocket Depth >= 4 mm of a Participant at the 3, 6 Months Post-SRP Completed at Baseline
Time Frame: Baseline to 3 months; Baseline to 6 months
|
The analysis is based on the measures of each participant.
Participant instead of site is used as unite for arm/group.
The measure, % sites with probing pocket depth >= 4 mm within each participant, indicates the portion of deep pocket in a participant.
Periodontal PD in millimeters is measured with a UNC-15 periodontal probe on 6 sites per tooth; The percentage of sites with Periodontal PD >= 4 mm within each participant was compared between measured time points.
|
Baseline to 3 months; Baseline to 6 months
|
Changes in Bleeding on Probing (BOP) Index of a Participant at 3, 6 Months After Treatment at Baseline
Time Frame: Baseline to 3 months; Baseline to 6 months
|
The analysis is based on the measures of each participant.
0 is the absence of gingival bleeding and 1 is the presence of gingival bleeding after probing and measuring for pocket depth.
Bleeding on probing index is defined as the percentage of sites with presence of gingival bleeding after probing per participant.
The value of bleeding on probing index ranges from 0 to 100 for each participant.
The bleeding on probing index per participant is compared between time points measured.
|
Baseline to 3 months; Baseline to 6 months
|
Change in Plaque Index of a Participant at 3, 6 Months After Treatment at Baseline
Time Frame: Baseline to 3 months; Baseline to 6 months
|
The analysis is based on the measures of each participant.
Plaque is visually measured on 6 sites per tooth; 0 is the absence of any plaque.
1 is the presence of plaque.
For each participant, 6 sites per tooth are evaluated.
The Plaque Index (PI) of each participant is defined as the percentage of sites with plaque.
The value of PI ranges from 0 to 100 for each participant.
The PI of each participant is assessed and compared between measured time points.
|
Baseline to 3 months; Baseline to 6 months
|
Change in Probing Pocket Depth at 3, 6 Months After Treatment in Diabetics and Non-diabetics
Time Frame: Baseline to 3 months; Baseline to 6 months
|
Probing depth (PD) or probing pocket depth (PPD), measured on six surfaces/tooth, is the distance in millimeters (mm) from the gingival margin to the base of the gingival pocket
|
Baseline to 3 months; Baseline to 6 months
|
Changes in Clinical Attachment Level at 3, 6 Months After Treatment at Baseline in Diabetics and Non-diabetics
Time Frame: Baseline to 3 months; Baseline to 6 months
|
The distance from the Cemento-enamel Junction (CEJ) to the free gingival margin is measured with a periodontal probe.
Millimeters of recession (loss of attachment) is recorded as a negative number; when the gingival margin is above the CEJ, the measurement (in millimeters) is recorded as positive.
|
Baseline to 3 months; Baseline to 6 months
|
Change in % Sites With Probing Pocket Depth >= 4 mm of a Participant at the 3, 6 Months Post-SRP Completed at Baseline in Diabetics and Non-diabetics
Time Frame: Baseline to 3 months; Baseline to 6 months
|
The analysis is based on the measure of each participant.
Periodontal PD in millimeters is measured with a UNC-15 periodontal probe on 6 sites per tooth; The percentage of sites with Periodontal PD >= 4 mm per participant is compared between measured time points.
|
Baseline to 3 months; Baseline to 6 months
|
Changes in Bleeding on Probing (BOP) Index of a Participant at 3, 6 Months After Treatment at Baseline in Diabetics and Non-diabetics
Time Frame: Baseline to 3 months; Baseline to 6 months
|
The analysis is based on the measures of each participant.
0 is the absence of gingival bleeding and 1 is the presence of gingival bleeding after probing and measuring for pocket depth.
Bleeding on probing index is defined as the percentage of sites with presence of gingival bleeding after probing per participant.
The value of bleeding on probing index ranges from 0 to 100 for each participant.
The bleeding on probing index per participant is compared between time points measured.
|
Baseline to 3 months; Baseline to 6 months
|
Change in Plaque Index of a Participant at 3, 6 Months After Treatment at Baseline in Diabetics and Non-diabetics
Time Frame: Baseline to 3 months; Baseline to 6 months
|
The analysis is based on the measures of each participant.
Plaque is visually measured on 6 sites per tooth; 0 is the absence of any plaque.
1 is the presence of plaque.
For each participant, 6 sites per tooth are evaluated.
The Plaque Index (PI) of each participant is defined as the percentage of sites with plaque.
The value of PI ranges from 0 to 100 for each participant.
The PI of each participant is assessed and compared between measured time points.
|
Baseline to 3 months; Baseline to 6 months
|
Changes in Hemoglobin A1c at 6 Months After Treatment
Time Frame: Baseline to 6 months
|
Hemoglobin in A1c (HbA1c) tells the average level of blood sugar over the prior 2 to 3 months.
Normal level is below 5.7%; 5.7%-6.4% indicates prediabetes; greater than 6.5% is indicative of diabetes.
|
Baseline to 6 months
|
Changes in Fasting Blood Glucose at 6 Months After Treatment
Time Frame: Baseline to 6 months
|
Fasting blood sugar/glucose (FBS/FBG) is tested with a blood sample taken after an overnight fast.
A fasting blood sugar level less than 100 mg/dL is normal; a fasting blood sugar level from 100 to 125 mg/dL is considered prediabetes; a level 126 mg/dL (7 mmol/L) or higher on two separate tests, indicates diabetes.
|
Baseline to 6 months
|
Change in High Sensitivity C-reactive Protein at 6 Months After Treatment
Time Frame: Baseline to 6 months
|
The high-sensitivity C-reactive protein (hs-CRP) blood test measures body inflammation indicating infection or a chronic inflammatory disease such as periodontitis or diabetes.
It also can be used to evaluate risk of developing coronary artery disease.
A normal reading is less than 10 milligram per liter (mg/L); a level greater than 10 mg/L is a sign of serious infection, trauma or chronic disease likely requiring further testing to determine cause
|
Baseline to 6 months
|
Changes in Hemoglobin A1c at 6 Months After Treatment in Diabetics and Non-diabetics
Time Frame: Baseline to 6 months
|
Hemoglobin in A1c (HbA1c) tells the average level of blood sugar over the prior 2 to 3 months.
Normal level is below 5.7%; 5.7%-6.4% indicates prediabetes; greater than 6.5% is indicative of diabetes.
|
Baseline to 6 months
|
Changes in Fasting Blood Glucose at 6 Months After Treatment in Diabetics and Non-diabetics
Time Frame: Baseline to 6 months
|
Fasting blood sugar/glucose (FBS/FBG) is tested with a blood sample taken after an overnight fast.
A fasting blood sugar level less than 100 mg/dL is normal; a fasting blood sugar level from 100 to 125 mg/dL is considered prediabetes; a level 126 mg/dL (7 mmol/L) or higher on two separate tests, indicates diabetes.
|
Baseline to 6 months
|
Change in High Sensitivity C-reactive Protein at 6 Months After Treatment in Diabetics and Non-diabetics
Time Frame: Baseline to 6 months
|
The high-sensitivity C-reactive protein (hs-CRP) blood test measures body inflammation indicating infection or a chronic inflammatory disease such as periodontitis or diabetes.
It also can be used to evaluate risk of developing coronary artery disease.
A normal reading is less than 10 milligram per liter (mg/L); a level greater than 10 mg/L is a sign of serious infection, trauma or chronic disease likely requiring further testing to determine cause
|
Baseline to 6 months
|
Shannon Index of the Subgingival Plaque Microbiome at Baseline and 6 Months
Time Frame: Baseline; 6 Months
|
Shannon index represents mean species diversity in a site at a local scale.
Shannon index quantifies the uncertainty in predicting the species identity of an individual that is taken at random from the dataset.
The minimum value is 0 and there is no maximum value.
High values mean high species diversities.
|
Baseline; 6 Months
|
Change in Distance to the Healthy Plane Based on the Subgingival Plaque Microbiome at 6 Months
Time Frame: Baseline to 6 Months
|
Analysis of microbiome community changes using the healthy plane (HP) as a reference.
A healthy plane was calculated by fitting a plane that minimizes the sum of squares of distances from HC samples to the nearest point on the plane.
The distance of each sample to the HP was then calculated.
Higher values of distance to HP mean microbiome community changes towards disease status
|
Baseline to 6 Months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Robert E Schifferle, DDS, PhD, University at Buffalo, State University of New York
Publications and helpful links
General Publications
- Nelson RG, Shlossman M, Budding LM, Pettitt DJ, Saad MF, Genco RJ, Knowler WC. Periodontal disease and NIDDM in Pima Indians. Diabetes Care. 1990 Aug;13(8):836-40. doi: 10.2337/diacare.13.8.836.
- Taylor GW, Burt BA, Becker MP, Genco RJ, Shlossman M, Knowler WC, Pettitt DJ. Non-insulin dependent diabetes mellitus and alveolar bone loss progression over 2 years. J Periodontol. 1998 Jan;69(1):76-83. doi: 10.1902/jop.1998.69.1.76.
- Arora N, Papapanou PN, Rosenbaum M, Jacobs DR Jr, Desvarieux M, Demmer RT. Periodontal infection, impaired fasting glucose and impaired glucose tolerance: results from the Continuous National Health and Nutrition Examination Survey 2009-2010. J Clin Periodontol. 2014 Jul;41(7):643-52. doi: 10.1111/jcpe.12258. Epub 2014 May 25.
- Engebretson S, Kocher T. Evidence that periodontal treatment improves diabetes outcomes: a systematic review and meta-analysis. J Periodontol. 2013 Apr;84(4 Suppl):S153-69. doi: 10.1902/jop.2013.1340017.
- Sgolastra F, Severino M, Pietropaoli D, Gatto R, Monaco A. Effectiveness of periodontal treatment to improve metabolic control in patients with chronic periodontitis and type 2 diabetes: a meta-analysis of randomized clinical trials. J Periodontol. 2013 Jul;84(7):958-73. doi: 10.1902/jop.2012.120377. Epub 2012 Oct 29.
- Engebretson SP, Hyman LG, Michalowicz BS, Schoenfeld ER, Gelato MC, Hou W, Seaquist ER, Reddy MS, Lewis CE, Oates TW, Tripathy D, Katancik JA, Orlander PR, Paquette DW, Hanson NQ, Tsai MY. The effect of nonsurgical periodontal therapy on hemoglobin A1c levels in persons with type 2 diabetes and chronic periodontitis: a randomized clinical trial. JAMA. 2013 Dec 18;310(23):2523-32. doi: 10.1001/jama.2013.282431.
- Borgnakke WS, Chapple IL, Genco RJ, Armitage G, Bartold PM, D'Aiuto F, Eke PI, Giannobile WV, Kocher T, Kornman KS, Lang NP, Madianos PN, Murakami S, Nishimura F, Offenbacher S, Preshaw PM, Rahman AU, Sanz M, Slots J, Tonetti MS, Van Dyke TE. The multi-center randomized controlled trial (RCT) published by the journal of the American Medical Association (JAMA) on the effect of periodontal therapy on glycated hemoglobin (HbA1c) has fundamental problems. J Evid Based Dent Pract. 2014 Sep;14(3):127-32. doi: 10.1016/j.jebdp.2014.04.017. Epub 2014 May 21.
- Colombo AP, Boches SK, Cotton SL, Goodson JM, Kent R, Haffajee AD, Socransky SS, Hasturk H, Van Dyke TE, Dewhirst F, Paster BJ. Comparisons of subgingival microbial profiles of refractory periodontitis, severe periodontitis, and periodontal health using the human oral microbe identification microarray. J Periodontol. 2009 Sep;80(9):1421-32. doi: 10.1902/jop.2009.090185.
- Colombo AP, Bennet S, Cotton SL, Goodson JM, Kent R, Haffajee AD, Socransky SS, Hasturk H, Van Dyke TE, Dewhirst FE, Paster BJ. Impact of periodontal therapy on the subgingival microbiota of severe periodontitis: comparison between good responders and individuals with refractory periodontitis using the human oral microbe identification microarray. J Periodontol. 2012 Oct;83(10):1279-87. doi: 10.1902/jop.2012.110566. Epub 2012 Feb 10.
- Kirst ME, Li EC, Alfant B, Chi YY, Walker C, Magnusson I, Wang GP. Dysbiosis and alterations in predicted functions of the subgingival microbiome in chronic periodontitis. Appl Environ Microbiol. 2015 Jan;81(2):783-93. doi: 10.1128/AEM.02712-14. Epub 2014 Nov 14.
- Wang J, Qi J, Zhao H, He S, Zhang Y, Wei S, Zhao F. Metagenomic sequencing reveals microbiota and its functional potential associated with periodontal disease. Sci Rep. 2013;3:1843. doi: 10.1038/srep01843.
- Perez-Chaparro PJ, Goncalves C, Figueiredo LC, Faveri M, Lobao E, Tamashiro N, Duarte P, Feres M. Newly identified pathogens associated with periodontitis: a systematic review. J Dent Res. 2014 Sep;93(9):846-58. doi: 10.1177/0022034514542468. Epub 2014 Jul 29.
- Beiswanger BB, Mallat ME, Jackson RD, Mau MS, Farah CF, Bosma ML, Bollmer BW, Hancock EB. Clinical effects of a 0.12% chlorhexidine rinse as an adjunct to scaling and root planing. J Clin Dent. 1992;3(2):33-8.
- Faveri M, Gursky LC, Feres M, Shibli JA, Salvador SL, de Figueiredo LC. Scaling and root planing and chlorhexidine mouthrinses in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Clin Periodontol. 2006 Nov;33(11):819-28. doi: 10.1111/j.1600-051X.2006.00994.x. Epub 2006 Sep 11.
- Abouassi T, Woelber JP, Holst K, Stampf S, Doerfer CE, Hellwig E, Ratka-Kruger P. Clinical efficacy and patients' acceptance of a rubber interdental bristle. A randomized controlled trial. Clin Oral Investig. 2014 Sep;18(7):1873-80. doi: 10.1007/s00784-013-1164-3. Epub 2014 Jan 10.
- Santos VR, Lima JA, Miranda TS, Goncalves TE, Figueiredo LC, Faveri M, Duarte PM. Full-mouth disinfection as a therapeutic protocol for type-2 diabetic subjects with chronic periodontitis: twelve-month clinical outcomes: a randomized controlled clinical trial. J Clin Periodontol. 2013 Feb;40(2):155-62. doi: 10.1111/jcpe.12040.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Stomatognathic Diseases
- Periodontal Diseases
- Mouth Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Periodontitis
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Dermatologic Agents
- Disinfectants
- Chlorhexidine
- Chlorhexidine gluconate
Other Study ID Numbers
- STUDY00000962
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Periodontitis
-
Azienda Socio Sanitaria Territoriale degli Spedali...Università degli Studi di FerraraCompletedPeriodontitis, Aggressive | Periodontitis, AdultItaly
-
Panineeya Mahavidyalaya Institute of Dental Sciences...Research Institute for Genetic and Human TherapyUnknownGeneralized Adult Periodontitis
-
Asem Mohammed Kamel AliCompletedMolar-incisor Pattern Grade C Periodontitis ( Localized Aggressive Periodontitis) | Generalized Grade C Periodontitis (Generalized Aggressive Periodontitis)Egypt
-
Columbia UniversityCompletedPeriodontal Diseases | Generalized Moderate Chronic Periodontitis | Generalized Severe Chronic PeriodontitisUnited States
-
Aga Khan UniversityCompletedChronic Apical PeriodontitisPakistan
-
Postgraduate Institute of Dental Sciences RohtakUnknownChronic Apical PeriodontitisIndia
-
University Hospital, Strasbourg, FranceRecruitingPeriodontitis, AdultFrance
-
October University for Modern Sciences and ArtsCompletedPeriodontitis, AdultEgypt
-
Loma Linda UniversityTerminated
-
PiLeJeCompletedProbiotics, PeriodontitisFrance
Clinical Trials on Chlorhexidine gluconate oral rinse
-
State University of New York at BuffaloNational Institute of Dental and Craniofacial Research (NIDCR)CompletedPneumoniaUnited States
-
University of TorontoUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Unity... and other collaboratorsCompletedMortality | Oral Health | Pain, Orofacial | Dryness, MouthCanada
-
Johns Hopkins Bloomberg School of Public HealthBill and Melinda Gates FoundationCompletedPeriodontitis | Premature Birth of NewbornNepal
-
University of PisaCompletedPeriodontal Diseases | Periodontal PocketItaly
-
University of TaubateFundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional de...Completed
-
NYU Langone HealthWithdrawn
-
The University of Hong KongTung Wah HospitalCompleted
-
University of TaubateFundação de Amparo à Pesquisa do Estado de São PauloCompletedPeriodontitisBrazil
-
Johns Hopkins UniversityRobert Wood Johnson FoundationCompleted
-
University of BaghdadCompletedPeriodontal Diseases | Mouth Diseases | Plaque Induced Gingivitis | Bleeding GumIraq